Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Haberman RH, Herati RS, Simon D, Samanovic M, Blank RB, Tuen M, Koralov SB, Atreya R, Tascilar K, Allen JR, Castillo R, Cornelius AR, Rackoff P, Solomon G, Adhikari S, Azar N, Rosenthal P, Izmirly P, Samuels J, Golden B, Reddy S, Neurath M, Abramson SB, Schett G, Mulligan MJ, Scher JU (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Book Volume: 80

Pages Range: 1339-1344

Journal Issue: 10

DOI: 10.1136/annrheumdis-2021-220597

Abstract

Objective To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment.

Authors with CRIS profile

David Simon Department of Medicine 3 – Rheumatology and Immunology Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur) Koray Tascilar Department of Medicine 3 – Rheumatology and Immunology Markus Neurath Lehrstuhl für Innere Medizin I Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

New York University (NYU)

United States (USA) (US)

How to cite

APA:

Haberman, R.H., Herati, R.S., Simon, D., Samanovic, M., Blank, R.B., Tuen, M.,... Scher, J.U. (2021). Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the Rheumatic Diseases, 80(10), 1339-1344. https://doi.org/10.1136/annrheumdis-2021-220597

MLA:

Haberman, Rebecca H., et al. "Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease." Annals of the Rheumatic Diseases 80.10 (2021): 1339-1344.

BibTeX: Download